Read The Lupus Book: A Guide for Patients and Their Families, Third Edition Online
Authors: Daniel J. Wallace
infants,
165–67
La (SSB) antibodies,
247
infections: defined,
236;
diagnosing,
237–38;
late-onset SLE,
168–69
fatal,
260;
infectious process,
173;
Latinos,
13
preventing,
238–39;
sinus,
123;
and steroids,
L-canavanine,
45, 185–86
leflunomide,
227–28,
228
inflammation: and arthritis,
175;
association
legal issues of lupus,
253–54
with lupus,
37, 175;
and fatigue,
192;
and
leprosy,
231–32
fever,
63;
as immune response,
17–22;
leukocytes.
See
white blood cells (leukocytes)
impact on productivity,
252;
inflammatory
levamisole,
235
bowel disease,
137;
inflammatory myositis,
Libman-Sacks endocarditis,
99–100, 161
174–75;
and lymphocytes,
26;
mixed
Life Events Inventory,
199
connective tissue disease (MCTD),
7, 67,
ligaments,
79,
80
90, 173–75;
and natural killer cells,
26;
and
lipstick,
45
neutrophils,
22–25, 26;
and pain,
199;
and
livedoid vasculitis,
75
scleroderma,
175;
and stress,
200;
therapies
livedo reticularis,
70, 75,
113,
161, 172
for,
207–12.
See also
nonsteroidal anti-
liver,
134,
140–43, 211
inflammatory drugs (NSAIDs)
local steroids,
220–21
influenza,
238–39
lovage,
189
[286]
Index
L-tryptophan,
45,
189,
205
menopause,
230, 240
lumbar puncture (spinal tap),
107, 119
menstrual problems,
129–30, 153, 156, 225–
lungs,
85–94,
86
lupoderma,
174
mesenteric infarction,
138–39
lupoid hepatitis,
140–41, 142–43
mesenteric vasculitis,
138–39, 260
lupus anticoagulant,
159–60, 162–63, 164, 258
metabolic system,
223
lupus band test,
76,
77,
171, 172
metabolites,
219
lupus clusters,
47
metals,
45
lupus cystitis,
150
methotrexate,
226–27,
228,
243, 246
Lupus Foundation of America,
xi,
11, 12, 195,
methyldopa,
53
methylprednisolone,
221,
222
lupus gene,
35, 248
Mexican border clinics,
205–6
lupus headache,
109–10,
113
microscopic polyangiitis,
175
lupus myelitis,
110–11
Mikulicz’s syndrome,
126
lupus nephritis,
64, 145–48, 149, 211
mineral supplements,
205
lupus panniculitis,
70, 76
miscarriages,
129
lymphadenopathy,
157
misoprostol,
137, 212
lymphatic system,
18–20, 23, 152–58, 233–34
mistletoe,
189
lymphocytes: abnormalities,
36;
activation of,
mitral valve prolapse,
100,
113
25;
in antibody production,
24
;
blood
mixed connective tissue disease (MCTD),
7,
filtering,
233–34;
chemotherapy’s impact on,
155;
described,
18;
formation of,
19
;
and monoarticular arthritis,
80
inflammation process,
26;
and steroids,
219;
monocytes,
18,
19, 21,
23–24
types of,
21
mononeuritis multiplex,
112
lymphopharesis,
234
mortality in lupus patients,
259–60
mothers,
166–67
Mackay, Ian,
142
Mount Sinai Hospital,
9
macrophages,
21,
23, 24,
24
mouth symptoms,
72, 123–24
magnesium salicylates,
208
movement disorders,
106
magnetic resonance imaging (MRI),
86, 119
mucosal ulcerations,
70, 72
major histocompatibility complex (MHC),
39–
multiple sclerosis,
107, 117
musculoskeletal system,
78–84;
avascular
malabsorption,
138
necrosis,
83;
bone marrow,
19
;
bone
malaise,
64.
See also
fatigue
mineralization study,
240–41;
bone scans,
malar rash,
9, 70, 73
171;
joints,
78–82,
79
;
muscle pain,
82–83,
malnutrition,
173
191;
muscle relaxants,
179;
osteoporosis,
83,
managing lupus,
230–35
231, 240–41, 258;
and the rheumatic review,
marigold,
187
61;
soft tissues,
78–82;
and steroids,
223
marriage issues,
202–3
myalgias,
82–83, 191
Massachusetts General Hospital,
9–10
myasthenia gravis,
117
Mayo Clinic,
10, 11
mycophenolate mofetil,
150, 227–28,
228,
264
meclofenamate,
211
myocardial dysfunction,
98–99
Medicare,
253–54
myocardial infarction,
100–102
medications: adverse reactions,
116–17, 168,
myocarditis,
97–98, 244
186, 202, 204–5, 217–18, 223–24, 224–25,
myofascial pain,
81
227, 230, 232;
compliance issues,
204–5,
myositis,
4, 7, 82, 121, 173, 174–75
257;
for depression,
201, 203;
disease
modifying drugs,
214–29;
drug approach to
nabumetone,
211
lupus,
181;
for fatigue,
193;
future of,
263–
naproxen,
210
64;
for infections,
238;
noncontraceptive,
nasal calcitonin,
241
230–31;
and pregnancy,
244–46;
safety of,
nasal symptoms,
72, 123
263.
See also specific drugs
National Arthritis Data Workshop,
11
meditation,
199, 204
National Institutes of Health (NIH),
207
meloxicam,
210
Native Americans,
13, 256
meningitis, aseptic,
105
natural killer cells,
18–20,
19, 21, 24,
26
Index
[287]
nausea,
136
panniculitis,
70, 76
neck,
121
paralysis,
105–6, 112
neonatal lupus,
12, 102, 165–67
parasitic organisms,
237
nephritis: glomerulonephritis,
144–45, 146–48;
parathyroid hormone,
241
interstitial,
149;
nephrotic syndrome,
64,
Parkinson’s disease,
117
145–49, 211, 256;
and pregnancy,
244
partial thromboplastin time (PTT),
66, 163
nephrons,
144
passion flowers,
189
nervous system.
See
central nervous system
pemphigoid lupus,
76
(CNS)
penicillin,
50
nettle,
189
peppermint,
190
neurologic manifestations of lupus,
61–62, 105–
peptic ulcer disease,
137
percussion,
61
neutrophils,
17,
21,
26, 30, 237
pericardiectomy,
97
New Zealand green-lipped mussel,
189
pericardium,
95, 96–97
nicotine,
194
peripheral nervous system,
106, 112, 232
nitrogen mustard,
225,
228,
243–44, 246
peritoneal dialysis,
232
non-organ-threatening disease,
7–8, 179
peritoneum,
134
nonsteroidal anti-inflammatory drugs (NSAIDs):
petechiae,
156
and anemia,
153;
and aseptic meningitis,
50;
Petri, Michelle,
194, 265–66
blood problems,
157;
choosing,
210–11;
phagocytes,
24
classes of,
209
;
CNS complications,
116;
phenobarbital,
53
and drug-induced lupus,
54;
and fevers,
63;
phenothiazine family of drugs,
53–54
future of,
261;
and GI problems,
136, 137;
phenylbutazone,
50, 205–6, 208–9, 258
and immune response,
23;
and infections,
phlebitis,
161
238;
liver dysfunction,
141;
precautions,
211–
phospholipids,
30, 159
12;
and pregnancy,
245, 248;
and renal
physical examinations,
61–62
function,
148;
research on,
264;
topical,
212;
pilocarpine,
126
types,
208–10,
209
piroxicam,
50, 210
nose,
72, 123
pituitary gland,
127,
128,
219–20
numbness,
106, 112,
113
placenta,
165, 251
nutrition,
184–86, 224,
241
Plaquenil (hydroxychloroquine),
125–26, 215–
occupational therapy,
191
plasma,
17,
19, 21,
21–22,
24,
234
oligoarthritis,
80
plasmapheresis,
157, 234, 246–47
omeprazole,
137
platelets: antiplatelet antibodies,
30, 31, 157;
ondasetron,
226
defects,
157;
described,
17;
in diagnosing
opportunistic organisms,
117, 236
optic neuritis,
122–23
pleurectomy,
89
oral steroids,
220
pleurisy,
87–89, 158
oral ulcers,
72
Pneumocystis carinii,
237
orbital myositis,
121
pokeroot,
190
organic brain syndrome,
115,
118
pollution,
47
organ-threatening lupus,
5, 7, 219
polyarteritis nodosa,
175
Osler, Sir William,
9, 104
polyarthritis,
80
osteoarthritis,
78
polymorphonuclear cells,
17,
19, 21
osteoporosis,
83, 231, 240–41, 258
polymorphous light eruption,
73
ovaries,
128
polymyalgia rheumatica,
12, 175
overlap syndrome,
7
polymyositis,
4, 173
oxaprozin,
210
positron emission tomography (PET) scans,
oxicam derivatives,
209
postpartum periods,
250–51
palindromic rheumatism,
170
prayer,
204, 259
palmar erythema,
113
prednisolone,
221,
262
palpation,
61
prednisone,
220,
221,
241, 246–47
pancreas,
134,
139–40
pregnancy,
161, 243–51
[288]
Index
premenstrual syndrome (PMS),
130
rehabilitation,
191–92
prevalence of lupus,
11–13, 173
relaxation exercises,
204
preventive strategies,
257–59,
259
releasing hormones,
127
proactive strategies,
257–59
remission of lupus,
258–59
procainamide,
53
renal problems,
144–50;
biopsy patterns,
147
;
productivity,
252–54
failure,
157;
fatal,
260;
and fertility,
243;
profundus,
76
and hormonal pathways,
128
;
kidney
progesterone,
127, 250
function,
144;
monitoring,
148;
nephrotic
prolactin,
127, 131
syndromes,
64, 145–49, 211, 256;
and